NCT02190721 2021-12-10
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Clinical Trials
9 trialsNCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT02521441 2018-02-23
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
EVIVE Biotechnology
Phase 2 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT00035620 2010-02-26
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00117897 2009-07-20
Treatment for Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed